CD274 and familial pancreatic carcinoma: Interestingly, unresectable, non-metastatic pancreatic cancer is also being investigated in a phase Ib clinical study (NCT02868632) to evaluate the efficacy of RT plus either anti-CTLA-4 mAb alone, anti-PD-L1 mAb alone, or the combination of both immune checkpoint inhibitors.